NASDAQ:RGEN Repligen (RGEN) Stock Price, News & Analysis $147.07 +1.90 (+1.31%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$145.34â–Ľ$150.7250-Day Range$119.79â–Ľ$167.3552-Week Range$110.45â–Ľ$211.13Volume824,833 shsAverage Volume673,405 shsMarket Capitalization$8.22 billionP/E Ratio588.30Dividend YieldN/APrice Target$188.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Repligen alerts: Email Address Repligen MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside28.1% Upside$188.38 Price TargetShort InterestBearish8.45% of Float Sold ShortDividend StrengthN/ASustainability-1.33Upright™ Environmental ScoreNews Sentiment0.80Based on 4 Articles This WeekInsider TradingSelling Shares$739,717 Sold Last QuarterProj. Earnings Growth34.48%From $1.45 to $1.95 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.74 out of 5 starsMedical Sector42nd out of 910 stocksBiological Products, Except Diagnostic Industry5th out of 155 stocks 4.4 Analyst's Opinion Consensus RatingRepligen has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRepligen has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Repligen's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.45% of the float of Repligen has been sold short.Short Interest Ratio / Days to CoverRepligen has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Repligen has recently increased by 0.23%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRepligen does not currently pay a dividend.Dividend GrowthRepligen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreRepligen has received a 68.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Spin filters", "Protein gels", and "Chromatography columns" products. See details.Environmental SustainabilityThe Environmental Impact score for Repligen is -1.33. Previous Next 2.1 News and Social Media Coverage News SentimentRepligen has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Repligen this week, compared to 5 articles on an average week.Search InterestOnly 4 people have searched for RGEN on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repligen insiders have sold 64.40% more of their company's stock than they have bought. Specifically, they have bought $449,938.00 in company stock and sold $739,717.00 in company stock.Percentage Held by InsidersOnly 1.20% of the stock of Repligen is held by insiders.Percentage Held by Institutions97.64% of the stock of Repligen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Repligen's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Repligen are expected to grow by 34.48% in the coming year, from $1.45 to $1.95 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repligen is 588.30, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 127.44.Price to Earnings Ratio vs. SectorThe P/E ratio of Repligen is 588.30, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 112.07.Price to Earnings Growth RatioRepligen has a PEG Ratio of 5.39. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRepligen has a P/B Ratio of 4.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Repligen's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About Repligen Stock (NASDAQ:RGEN)Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.Read More RGEN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RGEN Stock News HeadlinesSeptember 7 at 8:18 AM | finance.yahoo.comRepligen Corporation (RGEN) Fell Due to CEO TransitionAugust 30, 2024 | finance.yahoo.comRepligen (RGEN) Down 13.1% Since Last Earnings Report: Can It Rebound?September 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 29, 2024 | finance.yahoo.comRepligen Corporation (NASDAQ:RGEN) Shares Could Be 23% Below Their Intrinsic Value EstimateAugust 29, 2024 | americanbankingnews.comRepligen (NASDAQ:RGEN) Coverage Initiated by Analysts at Wells Fargo & CompanyAugust 23, 2024 | msn.comRepligen Swoons Ahead of Conference in BostonAugust 23, 2024 | msn.comRepligen Corporation (RGEN) Benefitted From Drug ApprovalAugust 23, 2024 | globenewswire.comRepligen Corporation to Present at Wells Fargo Healthcare ConferenceSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 20, 2024 | markets.businessinsider.comBuy Rating Affirmed: Overlooked Long-Term Benefits of Repligen’s Potential Maravai AcquisitionAugust 20, 2024 | markets.businessinsider.comJefferies Remains a Hold on Repligen (RGEN)August 17, 2024 | msn.comDo You Believe in the Growth Prospects of Repligen Corp. (RGEN)?August 16, 2024 | reuters.comExclusive: Repligen in bid for reagent vendor Maravai, sources sayAugust 2, 2024 | fool.comHere's Why Shares in This Hot Healthcare Stock Surged This WeekAugust 1, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Repligen Amid Strong Growth Prospects and Market ResilienceAugust 1, 2024 | markets.businessinsider.comRepligen’s Buy Rating Affirmed Amid Strong Growth and Strategic InitiativesAugust 1, 2024 | msn.comThese Analysts Revise Their Forecasts On Repligen Following Q2 ResultsJuly 31, 2024 | seekingalpha.comRepligen Corporation (RGEN) Q2 2024 Earnings Call TranscriptSee More Headlines Receive RGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repligen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/30/2024Today9/07/2024Next Earnings (Estimated)10/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:RGEN CUSIP75991610 CIK730272 Webwww.repligen.com Phone(781) 250-0111Fax781-250-0115Employees1,783Year Founded1981Price Target and Rating Average Stock Price Target$188.38 High Stock Price Target$220.00 Low Stock Price Target$155.00 Potential Upside/Downside+28.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$0.25 Trailing P/E Ratio588.30 Forward P/E Ratio101.43 P/E Growth5.39Net Income$41.58 million Net Margins-0.32% Pretax Margin1.69% Return on Equity3.36% Return on Assets2.41% Debt Debt-to-Equity Ratio0.26 Current Ratio6.65 Quick Ratio5.56 Sales & Book Value Annual Sales$602.35 million Price / Sales13.64 Cash Flow$2.95 per share Price / Cash Flow49.88 Book Value$35.31 per share Price / Book4.17Miscellaneous Outstanding Shares55,876,000Free Float55,205,000Market Cap$8.22 billion OptionableOptionable Beta0.94 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Anthony J. Hunt (Age 60)CEO & Director Comp: $885kMr. Olivier Loeillot (Age 54)President & Chief Commercial Officer Comp: $1.49MMr. Jason K. Garland (Age 50)CFO & Chief Compliance Officer Comp: $282.99kMr. James R. Bylund (Age 60)Chief Operating Officer Comp: $472.18kMs. Christine Gebski (Age 56)Senior Vice President of Filtration & Chromatography Comp: $396.09kMr. Ralf Kuriyel (Age 66)Senior Vice President of Research & Development Comp: $401.74kMr. Keith Lee RobinsonChief Information OfficerMs. Sondra S. NewmanGlobal Head of Investor RelationsMs. Kimberly A. CornwellGeneral Counsel & Global Head of LegalDr. Jaime M. Humara Ph.D.Senior Vice President of Global MarketingMore ExecutivesKey CompetitorsQiagenNYSE:QGENAcceleron PharmaNASDAQ:XLRNBio-TechneNASDAQ:TECHCRISPR TherapeuticsNASDAQ:CRSPDenali TherapeuticsNASDAQ:DNLIView All CompetitorsInsiders & InstitutionsGordian Capital Singapore Pte LtdBought 840 shares on 8/30/2024Ownership: 0.002%Dana Investment Advisors Inc.Bought 1,903 shares on 8/27/2024Ownership: 0.011%Ariadne Wealth Management LPBought 3,962 shares on 8/26/2024Ownership: 0.007%Truist Financial CorpSold 680 shares on 8/21/2024Ownership: 0.005%Susquehanna International Group LLPBought 6,800 shares on 8/16/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions RGEN Stock Analysis - Frequently Asked Questions How have RGEN shares performed this year? Repligen's stock was trading at $179.80 at the start of the year. Since then, RGEN stock has decreased by 18.2% and is now trading at $147.07. View the best growth stocks for 2024 here. How were Repligen's earnings last quarter? Repligen Co. (NASDAQ:RGEN) issued its quarterly earnings results on Tuesday, July, 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. The firm's revenue was down 3.2% compared to the same quarter last year. What is Tony J. Hunt's approval rating as Repligen's CEO? 13 employees have rated Repligen Chief Executive Officer Tony J. Hunt on Glassdoor.com. Tony J. Hunt has an approval rating of 52% among the company's employees. This puts Tony J. Hunt in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. Does Repligen have any subsidiaries? Repligen subsidiaries include ARTeSYN Biosolutions Holdings Ireland Limite, Non-Metallic Solutions Inc, Engineered Molding Technology LLC, C Technologies Inc., Repligen Europe B.V., Repligen GmbH, Repligen India Private Limited, and others. Who are Repligen's major shareholders? Top institutional investors of Repligen include Bank of New York Mellon Corp (2.45%), Conestoga Capital Advisors LLC (1.69%), Thrivent Financial for Lutherans (1.08%) and Dimensional Fund Advisors LP (0.77%). Insiders that own company stock include Anthony Hunt, Karen A Dawes, Jon Snodgres, Christine Gebski, Ralf Kuriyel, James Bylund, Martin D Madaus, Manner Carrie Eglinton, Nicolas Barthelemy and Thomas F Ryan Jr. View institutional ownership trends. How do I buy shares of Repligen? Shares of RGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Repligen own? Based on aggregate information from My MarketBeat watchlists, some other companies that Repligen investors own include NVIDIA (NVDA), Alibaba Group (BABA), Salesforce (CRM), Block (SQ), Advanced Micro Devices (AMD), DocuSign (DOCU) and Walt Disney (DIS). This page (NASDAQ:RGEN) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repligen Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Repligen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGEN Stock Alerts